Review of a New Multimodal Antidepressant Vortioxetine

1. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014; 10: 1297-1307.10.2147/NDT.S41387410697125075188Search in Google Scholar

2. Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003; 12 (3): 165.10.1002/mpr.138687853112830306Search in Google Scholar

3. Farsky I, Smetanka A, Dubinska S. Spirituality of patients with selected psychiatric disorders. Osetrovatelstvi a Porodni Asistence. 2012; 3 (3): 433-441.Search in Google Scholar

4. Halama P, Ondrejka I, Ziakova K, Farsky I. Existential and spiritual correlates of mental health in normal population and psychiatric patients. Ceskoslovenska psychologie. 2010; 54 (1): 42-57.Search in Google Scholar

5. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015; 4: 212290. Published October 8, 2015. Accessed June 30, 2016.Search in Google Scholar

6. Mørk A, Pehrson A, Brennum LT et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp. Ther. 2012; 340 (3): 666-675.Search in Google Scholar

7. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012; 40 (7): 1357-1365.10.1124/dmd.112.04461022496396Search in Google Scholar

8. Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013; 33: 727-736.10.1007/s40261-013-0117-6377515523975654Search in Google Scholar

9. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22 (7): 482-491.10.1016/j.euroneuro.2011.11.00822209361Search in Google Scholar

10. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27 (4): 215-223.10.1097/YIC.0b013e328354245722572889Search in Google Scholar

11. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology. 2014; 17 (10): 1557-67.10.1017/S1461145714000546416251924787143Search in Google Scholar

12. Häggström L, Nielsen RZ, Poulsen L, Danchenko N. A randomised, double blind, active controlled study of vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatment. Poster presented at: 26th Congress of the European College of Neuropsychop harmacology (ECNP); October 5-9, 2013; Barcelona, Spain.Search in Google Scholar

13. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsy - chopharmacol. 2012; 15 (5): 589-600.10.1017/S1461145711001027334929221767441Search in Google Scholar

14. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29 (3): 138-149.10.1097/YIC.0000000000000018397988724257717Search in Google Scholar

15. Henisberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73 (7): 953-959.10.4088/JCP.11m0747022901346Search in Google Scholar

16. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with Major Depres sive Disorder. Poster presented at: American Psychiatry Association Annual Meeting; May 18-22, 2013; San Francisco, USA.Search in Google Scholar

17. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16 (2): 313-321.10.1017/S146114571200072722963932Search in Google Scholar

18. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double blind, parallel, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of vortioxetine (LU AA21004) in acute treatment of adults with major depressive disorder. Poster presented at: American Psychiatry Association Annual Meeting; May 18-22, 2013; San Francisco, USA.Search in Google Scholar

19. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29 (3): 217-226.10.1185/03007995.2012.76160023252878Search in Google Scholar

20. Mahableshwarkar AR, Jacobsen P, Serenko M, Chcen Y, Trivedi MH. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD. Poster presented at: 166th Annual Meeting of the American Psychiatric Association (APA); May 18-22, 2013; San Francisco, USA.Search in Google Scholar

21. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012; 26 (11): 1408-1416.10.1177/026988111244186622495621Search in Google Scholar

22. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28 (10): 1717-1724.10.1185/03007995.2012.72503522978748Search in Google Scholar

23. Baldwin DS, Serenko M, Palo W, Lophaven S, Matz J. The safety and tolerability of vortioxetine (Lu AA21004) in the treatment of adults with major depressive disorder (MDD): a pooled analysis. Int J Psychiatry Clin Pract. 2013; 17 (Suppl. 2): 16-17.Search in Google Scholar

24. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics. 2015; 145: 43-57.10.1016/j.pharmthera.2014.07.00125016186Search in Google Scholar